Supplementary Figure S4 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies

Ekta Patel; Natalia V. Malkova; David Crowe; Magali Pederzoli-Ribeil; Damiano Fantini; Manoussa Fanny; Hanumantha Rao Madala; Kurt A. Jenkins; Oleg Yerov; Justin Greene; Wilson Guzman; Caitlin O’Toole; Jacob Taylor; Rebekah K. O’Donnell; Parker Johnson; Bernard B. Lanter; B N Ames; Jia Chen; Sallyann Vu; Hsin‐Jung Wu; Susan Cantin; Megan McLaughlin; Yu-Shan S. Hsiao; Dheeraj S. Tomar; Raphaël Rozenfeld; Lakshmanan Thiruneelakantapillai; Rónán C. O’Hagan; Benjamin Nicholson; Jennifer O’Neil; Carl Uli Bialucha

doi:10.1158/1535-7163.25541548

Key Points

Candidate XTX301 demonstrates potential to expand the therapeutic index of interleukin-12 therapy across preclinical solid tumor disease models.
Assessment using multi-color flow cytometry defines gating protocols to track tumor-infiltrating lymphocytes alongside splenic immune cell populations.
Findings highlight standardized profiling of splenic immune cell subsets under engineered interleukin-12; mouse model, further preclinical work needed.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Preclinical study demonstrates gating strategy for tumor-infiltrating and splenic immune cells under XTX301 treatment, suggesting methods to evaluate interleukin-12 therapeutic index widening.

Abstract

Supplemental Figure S4: Gating strategy for multi-color flow cytometry analysis of tumor-infiltrating and splenic immune cell populations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Patel et al. (2024) studied this question.

synapsesocial.com/papers/68e70788b6db643587680ffb https://doi.org/10.1158/1535-7163.25541548

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S4 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading